Conditionally replicating adenoviruses carrying mda-7/IL-24 for cancer therapy

Acta Oncologica

Volumn 51, Issue 3, 2012, Pages 285-292

  Jiang, Guan ^a,b   Zhang, Lei ^b   Xin, Yong ^a   Pei, Dong Sheng ^a   Wei, Zhi Ping ^a   Liu, Yan Qun ^a   Zheng, Jun Nian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b Center for Disease Control and Prevention of Xuzhou City   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CONDITIONALLY REPLICATING ADENOVIRUS; DACARBAZINE; DICHLOROACETIC ACID; DOXORUBICIN; INTERLEUKIN 19; INTERLEUKIN 20; INTERLEUKIN 24; LONTUCIREV; ONCOLYTIC ADENOVIRUS; STAT PROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; WORTMANNIN; ZD 55;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL SURVIVAL; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOTOXICITY; DNA REPLICATION; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; IMMUNE SYSTEM; LEUKOCYTE; MELANOCYTE; MELANOMA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SPLEEN; T LYMPHOCYTE; THYMUS; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM; VIRUS REPLICATION;

ADENOVIRIDAE; APOPTOSIS; GENE THERAPY; HUMANS; INTERLEUKINS; NEOPLASMS; VIRUS REPLICATION;

EID: 84859778026     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.621447     Document Type: Review

References (86)

1. Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS, Fisher PB. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc. Natl. Acad. Sci. USA 1996;93: 9160-5.
2. Lebedeva IV, Emdad L, Su ZZ, Gupta P, Sauane M, Sarkar D, et al. mda-7/IL-24, novel anticancer cytokine: Focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int. J. Oncol 2007;31:985-1007.
3. Emdad L, Lebedeva IV, Su ZZ, Gupta P, Sauane M, Dash R, et al. Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol. Ther. 2009;8:391-400.
4. Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, et al. The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol. Ther. 2010;128:375-84.
5. Gupta P, Su ZZ, Lebedeva IV, Sarkar D, Sauane M, Emdad L, et al. mda-7/IL-24: Multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol. Ther. 2006;111:596-628.
6. Eager R, Harle L, Nemunaitis J. Ad-MDA-7; INGN 241: A review of preclinical and clinical experience. Expert Opin Biol. Ther. 2008;8:1633-43.
7. Cunningham CC, Chada S, Merritt JA, Tong A, Senzer N, Zhang Y, et al. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: A phase I study. Mol. Ther. 2005;11:149-59.
8. Rein DT, Breidenbach M, Curiel DT. Current developments in adenovirus-based cancer gene therapy. Future Oncol. 2006;2:137-43.
9. Cody JJ, Douglas JT. Armed replicating adenoviruses for cancer virotherapy. Cancer Gene. Ther. 2009;16:473-88.
10. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med. 2001;7:781-7.
11. Liu XY. Targeting gene-virotherapy of cancer and its prosperity. Cell Res 2006;16:879-86.
12. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-defi cient human tumor cells. Science 1996;274:373-6.
13. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral effi cacy. Nat. Med. 2000;6:1134-9.
14. Harada JN, Berk AJ. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 1999;73:5333-44.
15. Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacombe MJ, et al. Oncolytic activity of the E1B-55 kDadeleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res. 2002;62:764-72.
16. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication compe tent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57:2559-63.
17. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H, et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. 2001; 61:517-25.
18. Breyer B, Jiang W, Cheng H, Zhou L, Paul R, Feng T, et al. Adenoviral vector-mediated gene transfer for human Gene. Therapy. Curr Gene. Ther. 2001;1:149-62.
19. Rivera AA, Davydova J, Schierer S, Wang M, Krasnykh V, Yamamoto M, et al. Combining high selectivity of replication with fi ber chimerism for effective adenoviral oncolysis of CARnegative melanoma cells. Gene. Ther. 2004;11:1694-702.
20. Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG, et al. Enhanced therapeutic effi cacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol. Ther. 2003;8:449-58.
21. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fl uorouracil in patients with recurrent head and neck cancer. Nat. Med. 2000;6:879-85.
22. Yoon AR, Kim JH, Lee YS, Kim H, Yoo JY, Sohn JH, et al. Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin. Hum Gene. Ther. 2006;17:379-90.
23. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. Subtraction hybridization identifi es a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 1995;11: 2477-86.
24. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Ann. Rev. Immunol. 2004;22:929-79.
25. Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka M, Su Z, Lebedeva IV, et al. Genomic structure, chromosomal localization and expression profi le of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene 2001;20:7051-63.
26. Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol 2001;167:3545-9.
27. Wang M, Tan Z, Zhang R, Kotenko SV, Liang P. Interleukin 24 (MDA-7/MOB-5) signals through two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2. J Biol Chem 2002;277:7341-7.
28. Parrish-Novak J, Xu W, Brender T, Yao L, Jones C, West J, et al. Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem 2002;277:47517-23.
29. Margue C, Kreis S. IL-24: Physiological and supraphysiological effects on normal and malignant cells. Curr. Med. Chem. 2010;17:3318-26.
30. Chada S, Mhashilkar AM, Liu Y, Nishikawa T, Bocangel D, Zheng M, et al. mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: Correlation with expression of bcl-2 family members. Cancer Gene. Ther. 2006;13:490-502.
31. Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanomadifferentiation associated gene-7 (mda-7/IL24): Biologic outcome in advanced cancer patients. Mol. Ther. 2005;11: 160-72.
32. Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P, Fisher PB. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc. Natl. Acad. Sci. U S A 2005;102:14034-9.
33. Sarkar D, Su ZZ, Fisher PB. Unique conditionally replication competent bipartite adenoviruses-cancer terminator viruses (CTV): Effi cacious reagents for cancer Gene. Therapy. Cell Cycle 2006;5:1531-6.
34. Sarkar D, Su ZZ, Park ES, Vozhilla N, Dent P, Curiel DT, et al. A cancer terminator virus eradicates both primary and distant human melanomas. Cancer Gene. Ther. 2008;15: 293-302.
35. Sarkar D, Lebedeva IV, Su ZZ, Park ES, Chatman L, Vozhilla N, et al. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res. 2007;67: 5434-42.
36. Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY, et al. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral effi cacy. Cell Res 2003;13: 481-9.
37. Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L, et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene. Ther. 2005;16:845-58.
38. Qian W, Liu J, Tong Y, Yan S, Yang C, Yang M, et al. Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia 2008;22:361-9.
39. Zhao L, Dong A, Gu J, Liu Z, Zhang Y, Zhang W, et al. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene. Ther. 2006;13:1011-22.
40. Hu Z, Robbins JS, Pister A, Zafar MB, Zhang ZW, Gupta J, et al. A modifi ed hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy. Cancer Gene. Ther. 2009;17:235-43.
41. Yu De B, Zhong SY, Yang M, Wang YG, Qian QJ, Zheng S, et al. Potent antitumor activity of double-regulated oncolytic adenovirus-mediated ST13 for colorectal cancer. Cancer Sci. 2009;100:678-83.
42. Wei N, Fan JK, Gu JF, He LF, Tang WH, Cao X, et al. A double-regulated oncolytic adenovirus with improved safety for adenocarcinoma therapy. Biochem. Biophys. Res. Commun 2009;388:234-9.
43. Wei N, Fan JK, Gu JF, Liu XY. Double-regulated oncolytic adenovirus-mediated interleukin-24 overexpression exhibits potent antitumor activity on gastric adenocarcinoma. Hum Gene. Ther. 2010;21:855-64.
44. Hildeman DA, Mitchell T, Aronow B, Wojciechowski S, K appler J, Marrack P. Control of Bcl-2 expression by reactive oxygen species. Proc. Natl. Acad. Sci. U S A 2003;100:15035-40.
45. S okoll LJ, Ellis W, Lange P, Noteboom J, Elliott DJ, Deras IL, et al. A multicenter evaluation of the PCA3 molecular urine test: Pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 2008;389:1-6.
46. Verhaegh GW, Van Bokhoven A, Smit F, Schalken JA, Bussemakers MJ. Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene. J Biol Chem 2000;275:37496-503.
47. Fan JK, Wei N, Ding M, Gu JF, Liu XR, Li BH, et al. Targeting Gene-ViroTherapy for prostate cancer by DD3-driven oncolytic virus-harboring interleukin-24 gene. Int. J. Cancer 2010;127:707-17.
48. Li B, Liu X, Fan J, Qi R, Bo L, Gu J, et al. A survivinmediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo. J Gene Med 2006;8:1232-42.
49. Kamizono J, Nagano S, Murofushi Y, Komiya S, Fujiwara H, Matsuishi T, et al. Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and effi cient viral replication. Cancer Res. 2005;65:5284-91.
50. Zhang KJ, Wang YG, Cao X, Zhong SY, Wei RC, Wu YM, et al. Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma double-regulated oncolytic adenovirus. Hum Gene. Ther. 2009;20:818-30.
51. Xiao LL, Wu YM, Qian J, Tan Y, Xie GL, Zhang KJ, et al. The antitumor effi cacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus. Cancer Biol. Ther. 2010;10: 242-50.
52. Carette JE, Graat HC, Schagen FH, Abou El Hassan MA, Gerritsen WR, Van Beusechem VW. Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site. J Gene Med 2005;7:1053-62.
53. Jin F, Kretschmer PJ, Hermiston TW. Identifi cation of novel insertion sites in the Ad5 genome that utilize the Ad splicing machinery for therapeutic gene expression. Mol. Ther. 2005;12:1052-63.
54. Young CS. The structure and function of the adenovirus major late promoter. Curr. Top. Microbiol. Immunol. 2003; 272:213-49.
55. Wold WS, Tollefson AE, Hermiston TW. E3 transcription unit of adenovirus. Curr. Top. Microbiol. Immunol. 1995;199: 237-74.
56. Luo J, Xia Q, Zhang R, Lv C, Zhang W, Wang Y, et al. Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene. Clin. Cancer Res. 2008;14:2450-7.
57. Jiang G, Liu YQ, Wei ZP, Pei DS, Mao LJ, Zheng JN. Enhanced anti-tumor activity by the combination of a conditionally replicating adenovirus mediated interleukin-24 and dacarbazine against melanoma cells via induction of apoptosis. Cancer Lett. 2010;294:220-8.
58. Zhong S, Yu D, Wang Y, Qiu S, Wu S, Liu XY. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer. Acta. Oncol. 2010;49:91-9.
59. Wu YM, Zhang KJ, Yue XT, Wang YQ, Yang Y, Li GC, et al. Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24. Acta Pharmacol Sin 2009;30:467-77.
60. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al. A mitochondria-K - Channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007;11:37-51.
61. Xiao L, Li X, Niu N, Qian J, Xie G, Wang Y. Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24. Mol Cell Biochem 2010;340:31-40.
62. Yang C, Tong Y, Ni W, Liu J, Xu W, Li L, et al. Inhibition of autophagy induced by overexpression of mda-7/interleukin-24 strongly augments the antileukemia activity in vitro and in vivo. Cancer Gene. Ther. 2010;17:109-19.
63. Lopes MB. Angiogenesis in brain tumors. Microsc Res Tech 2003;60:225-30.
64. De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989-91.
65. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, et al. High affi nity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993;72:835 - 46.
66. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (fl t) closely related to the fms family. Oncogene 1990;5:519-24.
67. Nicklin SA, Dishart KL, Buening H, Reynolds PN, Hallek M, Nemerow GR, et al. Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors. Cancer Lett. 2003;201:165-73.
68. Work LM, Ritchie N, Nicklin SA, Reynolds PN, Baker AH. Dual targeting of gene delivery by genetic modifi cation of adenovirus serotype 5 fi bers and cell-selective transcriptional control. Gene. Ther. 2004;11:1296-300.
69. Kaliberova LN, Krendelchtchikova V, Harmon DK, Stockard CR, Petersen AS, Markert JM, et al. CRAdRGDfl t-IL24 virotherapy in combination with chemotherapy of experimental glioma. Cancer Gene. Ther. 2009;16:794-805.
70. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin. Cancer Res. 2004;10:5299-312.
71. Homicsko K, Lukashev A, Iggo RD. RAD001 (everolimus) improves the effi cacy of replicating adenoviruses that target colon cancer. Cancer Res. 2005;65:6882-90.
72. Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007;7:141-8.
73. Jiang G, Wei ZP, Pei DS, Xin Y, Liu YQ, Zheng JN. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by Gene. Therapy. Biochem. Biophys. Res. Commun 2011;406:311-4.
74. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A. Effi cient gene transfer into human CD34( - ) cells by a retargeted adenovirus vector. J Virol 2000;74:2567-83.
75. Rebel VI, Hartnett S, Denham J, Chan M, Finberg R, Sieff CA. Maturation and lineage-specific expression of the coxsackie and adenovirus receptor in hematopoietic cells. Stem Cells 2000;18:176-82.
76. Jin J, Liu H, Yang C, Li G, Liu X, Qian Q, et al. Effective gene-viral therapy of leukemia by a new fi ber chimeric oncolytic adenovirus expressing TRAIL: In vitro and in vivo evaluation. Mol Cancer Ther 2009;8:1387-97.
77. Wang G, Li G, Liu H, Yang C, Yang X, Jin J, et al. E1B 55-kDa deleted, Ad5/F35 fi ber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies. J Gene Med 2009;11:477-85.
78. Dhar D, Spencer JF, Toth K, Wold WS. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor effi cacy in immunocompetent and immunosuppressed Syrian hamsters. J Virol 2009;83:2130-9.
79. Iankov ID, Blechacz B, Liu C, Schmeckpeper JD, Tarara JE, Federspiel MJ, et al. Infected cell carriers: A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol. Ther. 2007;15:114-22.
80. Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty BD, et al. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol. Ther. 2007;15: 123-30.
81. Cheong SC, Wang Y, Meng JH, Hill R, Sweeney K, Kirn D, et al. E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene. Ther. 2008;15:40-50.
82. Di Paolo NC, Tuve S, Ni S, Hellstrom KE, Hellstrom I, Lieber A. Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. Cancer Res. 2006;66:960-9.
83. Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. Mol. Ther. 2010;18: 243-50.
84. Steel JC, Morrison BJ, Mannan P, Abu-Asab MS, Wildner O, Miles BK, et al. Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncolytic adenovirus. Virology 2007;369:131-42.
85. Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K, et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res. 2006;66:1270-6.
86. Wildner O, Hoffmann D, Jogler C, Uberla K. Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs. Cancer Gene. Ther. 2003;10:791-802.